BioNTech SE Net Cash Flow 2019-2025 | BNTX

BioNTech SE net cash flow for the twelve months ending March 31, 2025 was $-5.240B, a 3.06% decline year-over-year.

  • BioNTech SE annual net cash flow for 2024 was $-2.058B, a 14.02% decline from 2023.
  • BioNTech SE annual net cash flow for 2023 was $-2.393B, a 118.65% decline from 2022.
  • BioNTech SE annual net cash flow for 2022 was $12.835B, a 2148.48% increase from 2021.

BioNTech SE Net Cash Flow 2019-2025 | BNTX

  • BioNTech SE annual net cash flow for 2024 was $-2.058B, a 14.02% decline from 2023.
  • BioNTech SE annual net cash flow for 2023 was $-2.393B, a 118.65% decline from 2022.
  • BioNTech SE annual net cash flow for 2022 was $12.835B, a 2148.48% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$218.6B
Amgen (AMGN)$164.4B
Gilead Sciences (GILD)$137B
Vertex Pharmaceuticals (VRTX)$120.7B
Bristol Myers Squibb (BMY)$97.7B
CSL (CSLLY)$84.2B
GSK (GSK)$75.8B
Regeneron Pharmaceuticals (REGN)$60.6B
Alnylam Pharmaceuticals (ALNY)$42.4B
Argenex SE (ARGX)$35B
Royalty Pharma (RPRX)$20.3B
Insmed (INSM)$19.5B
Biogen (BIIB)$18.7B
Illumina (ILMN)$16.2B
Genmab (GMAB)$14B
Genmab (GNMSF)$13.8B
Incyte (INCY)$13.3B
Moderna (MRNA)$12.7B
Exelixis (EXEL)$12.1B
BioMarin Pharmaceutical (BMRN)$11.4B
QIAGEN (QGEN)$11B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.1B
Exact Sciences (EXAS)$9.4B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.3B
Legend Biotech (LEGN)$8.1B
Roivant Sciences (ROIV)$7.8B
Revolution Medicines (RVMD)$7.1B